D.A. Davidson & Co. Cel Sci Corp Transaction History

D.A. Davidson & Co.

$12 Billion
Q3 2024

A detailed history of D.A. Davidson & Co. transactions in Cel Sci Corp stock. As of the latest transaction made, D.A. Davidson & Co. holds 30,800 shares of CVM stock, worth $19,712. This represents 0.0% of its overall portfolio holdings.

Number of Shares

30,800

Previous 32,800 6.1%

Holding current value

$19,712

Previous $38,000 15.79%

% of portfolio

0.0%

Previous 0.0%

25 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 13, 2024	SELL	$1.05 - $1.5 $2,100 - $3,000	-2,000 Reduced 6.1%	30,800 $32,000
Q2 2024 Jul 31, 2024	BUY	$1.11 - $1.85 $555 - $925	500 Added 1.55%	32,800 $38,000
Q1 2024 May 13, 2024	SELL	$1.63 - $3.08 $421,563 - $796,574	-258,628 Reduced 88.9%	32,300 $61,000
Q4 2023 Feb 09, 2024	BUY	$1.07 - $3.07 $264,426 - $758,682	247,128 Added 564.22%	290,928 $791,000
Q3 2023 Nov 08, 2023	SELL	$1.17 - $2.86 $567,905 - $1.39 Million	-485,389 Reduced 91.72%	43,800 $54,000
Q2 2023 Aug 10, 2023	SELL	$2.11 - $2.83 $37,138 - $49,810	-17,601 Reduced 3.22%	529,189 $1.28 Million
Q1 2023 Apr 25, 2023	BUY	$2.17 - $3.13 $357,874 - $516,196	164,919 Added 43.19%	546,790 $1.27 Million
Q4 2022 Feb 03, 2023	SELL	$1.99 - $3.52 $173,945 - $307,683	-87,410 Reduced 18.63%	381,871 $897,000
Q3 2022 Nov 07, 2022	SELL	$3.09 - $5.23 $23,669 - $40,061	-7,660 Reduced 1.61%	469,281 $1.45 Million
Q2 2022 Jul 28, 2022	BUY	$2.58 - $4.99 $123,682 - $239,215	47,939 Added 11.17%	476,941 $2.15 Million
Q1 2022 May 12, 2022	BUY	$3.93 - $7.7 $154,142 - $302,009	39,222 Added 10.06%	429,002 $1.69 Million
Q4 2021 Jan 31, 2022	BUY	$7.1 - $12.82 $57,410 - $103,662	8,086 Added 2.12%	389,780 $2.77 Million
Q3 2021 Nov 15, 2021	BUY	$7.64 - $12.49 $333,791 - $545,688	43,690 Added 12.93%	381,694 $4.2 Million
Q2 2021 Aug 10, 2021	BUY	$8.68 - $27.49 $82,026 - $259,780	9,450 Added 2.88%	338,004 $2.93 Million
Q1 2021 May 07, 2021	BUY	$12.0 - $27.64 $211,392 - $486,906	17,616 Added 5.67%	328,554 $5 Million
Q4 2020 Feb 10, 2021	BUY	$11.05 - $16.62 $88,411 - $132,976	8,001 Added 2.64%	310,938 $3.63 Million
Q3 2020 Nov 02, 2020	BUY	$11.69 - $14.54 $765,858 - $952,573	65,514 Added 27.59%	302,937 $3.86 Million
Q2 2020 Aug 10, 2020	SELL	$9.75 - $17.6 $2.03 Million - $3.66 Million	-208,174 Reduced 46.72%	237,423 $3.54 Million
Q1 2020 May 05, 2020	SELL	$7.54 - $17.05 $402,666 - $910,538	-53,404 Reduced 10.7%	445,597 $5.14 Million
Q4 2019 Feb 14, 2020	SELL	$6.71 - $9.55 $198,072 - $281,906	-29,519 Reduced 5.59%	499,001 $4.57 Million
Q3 2019 Nov 05, 2019	BUY	$6.0 - $9.6 $65,520 - $104,832	10,920 Added 2.11%	528,520 $4.73 Million
Q2 2019 Aug 13, 2019	BUY	$3.77 - $8.67 $444,483 - $1.02 Million	117,900 Added 29.5%	517,600 $4.34 Million
Q1 2019 May 13, 2019	BUY	$2.58 - $3.54 $254,130 - $348,690	98,500 Added 32.7%	399,700 $1.42 Million
Q4 2018 Jan 29, 2019	BUY	$2.65 - $4.26 $427,180 - $686,712	161,200 Added 115.14%	301,200 $864,000
Q3 2018 Nov 13, 2018	BUY	$0.83 - $4.16 $116,200 - $582,400	140,000 New	140,000 $567,000

Others Institutions Holding CVM

# of Institutions

Shares Held

Call Options Held

27.1K

Put Options Held

150K

View Full List

About CEL SCI CORP

Ticker CVM
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,367,500
Market Cap $27.8M
Description
CEL-SCI Corporation engages in the research and development of immunotherapy for the treatment of cancer and infectious diseases. The company's lead investigational immunotherapy is Multikine, which is under phase III clinical trial for the treatment of head and neck cancer. Its Ligand Epitope Antigen Presentation System (LEAPS), a pre-clinical ...

More about CVM

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of D.A. Davidson & Co., based on Form 13F filings with the SEC.

News

Stay updated on D.A. Davidson & Co. with notifications on news.

Account